Leponex
Categoria
Leponex Marchi, Leponex Analoghi
Leponex Marchi miscela
Leponex Formula chimica
C18H19ClN4
Leponex RX link
http://www.rxlist.com/cgi/generic3/clozapine.htm
Leponex FDA foglio
Leponex DMS (foglio di materiale di sicurezza)
Leponex Sintesi di riferimento
Nessuna informazione disponibile
Leponex Peso molecolare
326.823 g/mol
Leponex Temperatura di fusione
183-184 oC
Leponex H2O Solubilita
11,8 mg / L
Leponex Stato
Solid
Leponex LogP
2.502
Leponex Forme di dosaggio
Compressa
Leponex Indicazione
Per la gestione dei pazienti schizofrenici gravemente malati che non rispondono adeguatamente al trattamento farmaco standard per la schizofrenia
Leponex Farmacologia
Clozapina è un agente psicotrope appartenente alla classe chimica dei derivati benzisossazolico ed è indicato per il trattamento della schizofrenia. Clozapina è un antagonista selettivo monoaminergico con alta affinità per il tipo di serotonina 2 (5HT2), tipo dopamina 2 (D2), 1 e 2 adrenergici e recettori H1 istaminergici. Clozapina agisce come un antagonista dei recettori, ma con minore potenza. Antagonismo in altri recettori di dopamina e 5HT2 con affinità simili potrebbero spiegare alcuni degli altri effetti terapeutici e collaterali della Clozapina. Antagonismo Clozapina di muscarinici M1-5 recettori possono spiegare i suoi effetti anticolinergici. Antagonismo Clozapina di recettori H1 dell'istamina possono spiegare la sonnolenza osservata con questo farmaco. Antagonismo Clozapina di recettori adrenergici a1 può spiegare l' ipotensione ortostatica osservato con questo farmaco.
Leponex Assorbimento
Rapido e quasi completo
Leponex Tossicita
Nessuna informazione disponibile
Leponex Informazioni paziente
PATIENT INFORMATION
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
� Patients who are to receive CLOZARIL should be warned about the significant risk of developing agranulocytosis. They should be informed that weekly blood tests are required for the first 6 months, if acceptable WBC counts (WBC � 3000/mm3, ANC � 1500/mm3) have been maintained during the first 6 months of continuous therapy, then WBC counts can be monitored every other week in order to monitor for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made available only through a special program designed to ensure the required blood monitoring. Patients should be advised to report immediately the appearance of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration or other possible signs of infection.
Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection.
� Patients should be informed of the significant risk of seizure during CLOZARIL treatment, and they should be advised to avoid driving and any other potentially hazardous activity while taking CLOZARIL.
� Patients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration.
� Patients should be informed that if they stop taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage, but should contact their physician for dosing instructions.
� Patients should notify their physician if they are taking, or plan to take, any prescription or over-the-counter drugs or alcohol.
� Patients should notify their physician if they become pregnant or intend to become pregnant during therapy.
� Patients should not breast-feed an infant if they are taking CLOZARIL.
Leponex Atto interessato organismi
Gli esseri umani e altri mammiferi
